Norman, R. J., Dewailly, D., Legro, R. S., and Hickey, T. E. Polycystic ovary syndrome. Lancet 2007;370:685–697.Google Scholar

Dokras, A., Clifton, S., Futterweit, W., and Wild, R. Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 2012;97:225–230.Google Scholar

Webber, L. J., Stubbs, S., Stark, J., et al. Formation and early development of follicles in the polycystic ovary. Lancet 2003;362:1017–1021.Google Scholar

Pellatt, L., Rice, S., and Mason, H. D. Anti-Mullerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction 2010;139;825–833.Google Scholar

Catteau-Jonard, S., Jamin, S. P., Leclerc, A., et al. Anti-Mullerian hormone, its receptor, FSH receptor, and androgen receptor genes are overexpressed by granulosa cells from stimulated follicles in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:4456–4461.Google Scholar

Homburg, R., Ray, A., Bhide, P., et al. The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Hum Reprod 2013;28;1077–1083.Google Scholar

Homburg, R. and Crawford, G. The role of AMH in anovulation associated with PCOS: a hypothesis. Hum Reprod 2014;29:1117–1121.Google Scholar

Visser, J. A., de Jong, F., Laven, J. S., and Themmen, A. P. Anti-Mullerian hormone: a new marker for ovarian function. Reproduction 2006;131:1–9.Google Scholar

Laven, J. S., Mulders, A. G., Visser, J. A., et al. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004.;89;318–323.Google Scholar

Vendola, K. A., Zhou, J., Adesanya, O. O., et al. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest 1998;101:2622–2629.Google Scholar

Pigny, P., Merlen, E., Robert, Y., et al. Elevated serum level of antimullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003;88: 5957–5962.Google Scholar

La Marca, A., Malmusi, S., Giulini, S., et al. Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod 2004;19:2738–2741.Google Scholar

Pinilla, L., Aguilar, E., Dieguez, C., et al. Kisspeptins and reproduction: physiological roles and regulatory mechanisms. Physiol Rev 2012;3:1235–1316Google Scholar

Skorupskaite, K., George, J., and Anderson, R. The kisspeptin-GnRH pathway in human reproductive health and disease. Hum Reprod Update 2014;20:485–500.Google Scholar

Garcia-Galiano, D., Pinilla, L., and Tena-Sempere, M. Sex steroids and the control of the Kiss1 system: developmental roles and major regulatory actions. J Neuroendocrinol 2012;24:22–33.Google Scholar

Cernea, M., Padmanabhan, V., Goodman, R. L., et al. Prenatal testosterone treatment leads to changes in the morphology of KNDy neurons, their inputs, and projections to GnRH cells in female sheep. Endocrinol 2015;156:3277–3291.Google Scholar

Kondo, M., Osuka, S., Iwase, A., et al. Increase of kisspeptin-positive cells in the hypothalamus of a rat model of polycystic ovary syndrome. Metab Brain Dis 2016;31:673–81.Google Scholar

Abbott, D. H., Dumesic, D. A., and Franks, S. Developmental origin of polycystic ovary syndrome–a hypothesis. Endocrinol 2002;174:1–5.Google Scholar

Falbo, A., Rocca, M., Russo, T., et al. Changes in androgens and insulin sensitivity indexes throughout pregnancy in women with polycystic ovary syndrome (PCOS): relationships with adverse outcomes. J Ovarian Res 2010;3:23.Google Scholar

Hines, M., Golombok, S., Rust, J., et al. Testosterone during pregnancy and gender role behavior of pre-school children: a longitudinal, population study. Child Dev 2002;73:1678–1687.Google Scholar

Kosidou, K., Dalman, C., Widman, L., et al. Maternal polycystic ovary syndrome and the risk of autism spectrum disorders in the offspring: a population-based nationwide study in Sweden. Mol Psychiatry 2015; Dec 8 doi: 10.1038/mp.2015.183. [Epub ahead of print]Google Scholar

Baron-Cohen, S., Auyeung, B., Nørgaard-Pedersen, B., et al. Elevated fetal steroidogenic activity in autism. Molecular Psychiatry 2015;20:369–376.Google Scholar

Maliqueo, M., Lara, H. E., Sánchez, F., et al. Placental steroidogenesis in pregnant women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2013;166:151–155.Google Scholar

Padmanabhan, V. and Veiga-Lopez, A. Sheep models of polycystic ovary syndrome phenotype. Mol Cell Endocrinol 2013;373:8–20.Google Scholar

Franks, S., McCarthy, M. I., and Hardy, K. Development of polycystic ovary syndrome: involvement of genetic and environmental factors. Int J Androl 2006;29:278–285, discussion 286–290.Google Scholar

Hart, R., Sloboda, A., Doherty, D., et al. Circulating maternal testosterone concentrations at 18 weeks of gestation predict circulating levels of antimullerian hormone in adolescence: a prospective cohort study, Fertil Steril 2010:94:1544–1547.Google Scholar

Sun, M., Maliqueo, M., Benrick, A., et al. Maternal androgen excess reduces placental and fetal weights, increases placental steroidogenesis, and leads to long-term health effects in their female offspring. Am J Physiol Endocrinol Metab 2012;303:E1373–E1385.Google Scholar

Palomba, S., Russo, T., Falbo, A., et al. Macroscopic and microscopic findings of the placenta in women with polycystic ovary syndrome. Hum Reprod 2013;28:2838–2847.Google Scholar